China’s Breakthrough Obesity Drug Mazdutide Achieves Record Weight Loss in Global Study
A landmark Phase 3 clinical study of mazdutide, the world’s first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been…
A landmark Phase 3 clinical study of mazdutide, the world’s first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been…